ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Outsourcing

Johnson Matthey re-ups Sarepta supply contract

by Rick Mullin
September 11, 2020 | APPEARED IN VOLUME 98, ISSUE 35

 

The British chemical company Johnson Matthey has landed a 5-year extension of a contract with Sarepta Therapeutics to supply starting materials for the drug firm’s phosphorodiamidate morpholino oligomer (PMO) and peptide PMO drug candidates for the treatment of Duchenne muscular dystrophy. Matthey will produce the PMO materials at facilities in West Deptford, New Jersey, and Devens, Massachusetts.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment